Importance of the 1-month-effect of nadolol on portal pressure in predicting failure of prevention of rebleeding in cirrhosis.
Sacerdoti
D
D
Merkel
C
C
Gatta
A
A
D004932:Esophageal and Gastric Varices / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D005500:Follow-Up Studies; D006471:Gastrointestinal Hemorrhage / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy*; D008103:Liver Cirrhosis / Q000150:complications* / Q000453:epidemiology; D008107:Liver Diseases / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D008297:Male; D009248:Nadolol / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D009248:Nadolol